弥合骨髓移植和CAR-T细胞治疗血液肿瘤之间的差距。

4区 医学 Q2 Biochemistry, Genetics and Molecular Biology
Babak Arjmand, Fatemeh Shahrahmani, Alieh Mirzaei, Sepideh Alavi-Moghadam, Rasta Arjmand, Mostafa Rezaei-Tavirani, Seyed Mohammadamin Nejati-Niyaki, Bagher Larijani, Ghasem Janbabaei, Seied Asadollah Mousavi, Abbas Hajifathali
{"title":"弥合骨髓移植和CAR-T细胞治疗血液肿瘤之间的差距。","authors":"Babak Arjmand, Fatemeh Shahrahmani, Alieh Mirzaei, Sepideh Alavi-Moghadam, Rasta Arjmand, Mostafa Rezaei-Tavirani, Seyed Mohammadamin Nejati-Niyaki, Bagher Larijani, Ghasem Janbabaei, Seied Asadollah Mousavi, Abbas Hajifathali","doi":"10.1007/5584_2025_862","DOIUrl":null,"url":null,"abstract":"<p><p>Bone marrow transplantation and chimeric antigen receptor T cell therapy have become two important treatment modalities for hematological malignancies, each having different mechanisms of action and therapeutic roles. This chapter focuses on the chronological development and obstacles of bone marrow transplantation, the paradigm-shifting impact of chimeric antigen receptor T cell therapy, and further integrative approaches. The complementary roles of these modalities are emphasized given their optimal timing, selection of patients, and the development of novel strategies to improve therapeutic outcomes. Challenges such as cytokine release syndrome, graft-versus-host disease, and immune suppression are critically scrutinized. The future perspectives highlight the development of synergistic approaches, refining patient-centered treatments, and addressing long-term quality-of-life concerns. It is with this aim that the discussion below might help bridge these modalities through interdisciplinary efforts toward more effective, personalized, and sustainable treatments for cancer.</p>","PeriodicalId":7270,"journal":{"name":"Advances in experimental medicine and biology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bridging the Gap Between Bone Marrow Transplantation and CAR-T Cell Therapy in Hematological Cancers.\",\"authors\":\"Babak Arjmand, Fatemeh Shahrahmani, Alieh Mirzaei, Sepideh Alavi-Moghadam, Rasta Arjmand, Mostafa Rezaei-Tavirani, Seyed Mohammadamin Nejati-Niyaki, Bagher Larijani, Ghasem Janbabaei, Seied Asadollah Mousavi, Abbas Hajifathali\",\"doi\":\"10.1007/5584_2025_862\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Bone marrow transplantation and chimeric antigen receptor T cell therapy have become two important treatment modalities for hematological malignancies, each having different mechanisms of action and therapeutic roles. This chapter focuses on the chronological development and obstacles of bone marrow transplantation, the paradigm-shifting impact of chimeric antigen receptor T cell therapy, and further integrative approaches. The complementary roles of these modalities are emphasized given their optimal timing, selection of patients, and the development of novel strategies to improve therapeutic outcomes. Challenges such as cytokine release syndrome, graft-versus-host disease, and immune suppression are critically scrutinized. The future perspectives highlight the development of synergistic approaches, refining patient-centered treatments, and addressing long-term quality-of-life concerns. It is with this aim that the discussion below might help bridge these modalities through interdisciplinary efforts toward more effective, personalized, and sustainable treatments for cancer.</p>\",\"PeriodicalId\":7270,\"journal\":{\"name\":\"Advances in experimental medicine and biology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in experimental medicine and biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/5584_2025_862\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in experimental medicine and biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/5584_2025_862","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

摘要

骨髓移植和嵌合抗原受体T细胞治疗已成为血液系统恶性肿瘤的两种重要治疗方式,各自具有不同的作用机制和治疗作用。本章重点介绍骨髓移植的时间发展和障碍,嵌合抗原受体T细胞治疗的范式转移影响,以及进一步的综合方法。这些模式的互补作用强调了他们的最佳时机,选择患者,并制定新的策略,以改善治疗结果。挑战,如细胞因子释放综合征,移植物抗宿主病,和免疫抑制严格审查。未来的观点强调协同方法的发展,完善以患者为中心的治疗,并解决长期生活质量问题。正是出于这个目的,下面的讨论可能有助于通过跨学科的努力将这些模式连接起来,以实现更有效、个性化和可持续的癌症治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Bridging the Gap Between Bone Marrow Transplantation and CAR-T Cell Therapy in Hematological Cancers.

Bone marrow transplantation and chimeric antigen receptor T cell therapy have become two important treatment modalities for hematological malignancies, each having different mechanisms of action and therapeutic roles. This chapter focuses on the chronological development and obstacles of bone marrow transplantation, the paradigm-shifting impact of chimeric antigen receptor T cell therapy, and further integrative approaches. The complementary roles of these modalities are emphasized given their optimal timing, selection of patients, and the development of novel strategies to improve therapeutic outcomes. Challenges such as cytokine release syndrome, graft-versus-host disease, and immune suppression are critically scrutinized. The future perspectives highlight the development of synergistic approaches, refining patient-centered treatments, and addressing long-term quality-of-life concerns. It is with this aim that the discussion below might help bridge these modalities through interdisciplinary efforts toward more effective, personalized, and sustainable treatments for cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in experimental medicine and biology
Advances in experimental medicine and biology 医学-医学:研究与实验
CiteScore
5.90
自引率
0.00%
发文量
465
审稿时长
2-4 weeks
期刊介绍: Advances in Experimental Medicine and Biology provides a platform for scientific contributions in the main disciplines of the biomedicine and the life sciences. This series publishes thematic volumes on contemporary research in the areas of microbiology, immunology, neurosciences, biochemistry, biomedical engineering, genetics, physiology, and cancer research. Covering emerging topics and techniques in basic and clinical science, it brings together clinicians and researchers from various fields.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信